|
AIM: RENE |
|
12 September 2018 |
ReNeuron Group plc
("ReNeuron" or the "Company")
Result of AGM
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that all resolutions put to shareholders at its Annual General Meeting, held earlier today, were duly passed.
ENDS
Enquiries:
|
ReNeuron |
+44 (0) 20 3819 8400 |
|
Olav Hellebø, Chief Executive Officer |
|
|
Michael Hunt, Chief Financial Officer |
|
|
Buchanan |
+44 (0) 20 7466 5000 |
|
Mark Court, Sophie Wills, Tilly Abraham |
|
|
|
|
|
Stifel Nicolaus Europe Limited Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker) |
+44 (0) 20 7710 7600 |
|
N+1 Singer Advisory LLP Mark Taylor (Joint Broker) |
+44 (0) 20 7496 3000 |
About ReNeuron
ReNeuron is a leading, clinical-stage cell therapy development company. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.
ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. The Company has therapeutic candidates in clinical development for disability as a result of stroke and for the blindness-causing disease, retinitis pigmentosa.
ReNeuron is also advancing its proprietary exosome technology platform as a potential new nanomedicine targeting cancer and as a potential delivery system for drugs that would otherwise be unable to reach their site of action.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.
